美国安进地舒单抗注射液纳入医保了吗

(trade name Prolia) is a drug that targets the RANK ligand. Compared with bisphosphonates that have been clinically used for a long time, this drug has the advantage of significantly prolonging the occurrence time of bone damage-related events. On May 28, 2010, denosumab was approved for marketing by the European Commission. On June 2, 2010, it was approved by the US FDA for use in postmenopausal women with the risk of osteoporosis. It was approved for marketing in my country in 2019.

The manufacturer of denosumab injection is the American company Amgen. Amgen is committed to benefiting patients with serious diseases around the world by unleashing the potential of biology. Focusing on disease areas with huge medical needs that are far from being met, and leveraging its advanced experience in biopharmaceuticals, it aims to make outstanding contributions to improving human health and quality of life.

Desosumab can specifically target receptor activator of nuclear factor kappa B ligand (RANK), inhibit osteoclast activation and development, reduce bone resorption, and increase bone density. Although the approval of denosumab in my country has brought new and effective options to domestic patients, many patients find it difficult to afford it because the price of the original drug is usually relatively high. For domestic patients, drugs are included in the national medical insurance and reimbursement through medical insurance is one of the ways to reduce the financial pressure of drug use. So, has Amgen Desosumab Injection in the United States been included in the medical insurance?

According to the latest news, in the 2020 "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalogue", as the world's first RANKL inhibitor, it was successfully selected into the medical insurance catalog. In other words, denosumab is already a medical insurance drug and can be reimbursed through medical insurance. Patients can consult local authorities for specific medical insurance information.

Recommended related hot articles: /newsDetail/91042.html